Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Delcath executes melphalan supply agreement with Synerx and Bioniche Teoranta

Delcath Systems, Inc. announced today that it has executed a multi-year supply agreement with Synerx Pharma, LLC and Bioniche Teoranta, an affiliate of Mylan, Inc., for the supply of Delcath's branded melphalan hydrochloride for injection ("melphalan"). Melphalan is the chemotherapeutic drug used with Delcath's Chemosaturation system in its Phase III clinical study for the treatment of patients with hepatic metastases from ocular or cutaneous melanoma.

15 Oct 2010

Prolong Pharmaceuticals receives $30 million from private investor group

Prolong Pharmaceuticals today announced that the company has received a commitment of $30 million in funding from a private investor group. The monies will be dedicated to the company's continuing research and development efforts and clinical programs targeting anemias resulting from oxygen deficiency.

15 Oct 2010

Acetadote Injection is now commercially available in Australia

Cumberland Pharmaceuticals Inc. and Phebra Pty Ltd. today announced that Acetadote (acetylcysteine) Injection, an injectable product used to treat acetaminophen (paracetamol) overdose, is now commercially available in the Australian market. Phebra Pty Ltd., an Australian-based specialty pharmaceutical company, has an exclusive license from U.S.-based Cumberland Pharmaceuticals to market and distribute the product in Australia.

15 Oct 2010

NinePoint announces completion of $33 million Series A financing

NinePoint Medical, Inc., an emerging leader in the development of in vivo pathology devices, today announced it has completed a $33 million Series A financing led by Third Rock Ventures and Prospect Venture Partners. The company also announced the establishment of its corporate headquarters in Cambridge, Mass. where Charles Carignan, M.D., serves as president and chief executive officer.

14 Oct 2010

Highlighting calories, saturated fat, trans fat, and sodium in food packaging nutrition rating systems needed

Nutrition rating systems and symbols on the fronts of food packaging would be most useful to shoppers if they highlighted four nutrients of greatest concern - calories, saturated fat, trans fat, and sodium - says a new report from the Institute of Medicine. These food components are routinely overconsumed and associated most strongly with diet-related health problems affecting many Americans, including obesity, heart disease, high blood pressure, Type 2 diabetes, and certain types of cancer.

14 Oct 2010

Sunshine Biopharma to enter Adva-27a Phase I clinical trial for Multi-Drug Resistant breast cancer

Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it issued a letter to its shareholders advising that it had filed for patent protection worldwide and expects to enter Phase I clinical trials for its principal drug, Adva-27a, beginning with GMP manufacturing and animal tox studies.

14 Oct 2010

Risingsun signs consent decree to stop selling unapproved drugs

The U.S. Food and Drug Administration today announced that Toby McAdam and Greta Armstrong, doing business as Risingsun Health and The Center for Complimentary and Alternative Health of Livingston, Montana, have signed a consent decree that prohibits them from manufacturing and selling unapproved new drugs and adulterated or misbranded dietary supplements in violation of the law.

14 Oct 2010

Ligand launches Viviant in Japan and Spain for postmenopausal osteoporosis

Ligand Pharmaceuticals Incorporated today announced that its partner Pfizer, Inc. launched Viviant® (Bazedoxifene) in Japan for the treatment of postmenopausal osteoporosis. Under the brand name Conbriza®, the drug is also marketed in Spain through a co-promotion with Almirall, an international pharmaceutical company based in Spain.

14 Oct 2010

Medicago and PATH partner on development of broad coverage influenza vaccine

Medicago Inc., a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has been awarded $946,000 in funding by U.S.-based PATH pursuant to a research collaboration agreement. Medicago and PATH will work together on a broad coverage influenza vaccine based on Medicago's proprietary plant-based Virus-Like Particle (VLP) technologies for the developing world.

13 Oct 2010

Natus announces acquisition of Medix

Natus Medical Incorporated today announced that it has acquired Medix, a leader in the development, manufacturing, and sales of devices for newborn care in Latin America. Medix, based in Argentina, manufactures incubators for use in hospital nurseries and neonatal intensive care units, transport incubators for use in ambulances and other emergency vehicles, infant warmers, and LED based phototherapy devices.

13 Oct 2010

ImmunoCellular develops ICT-107 cell-based vaccine for GBM treatment

ImmunoCellular Therapeutics, a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that it has developed an innovative method for manufacturing the company's lead product candidate, ICT-107, a dendritic cell-based vaccine for the treatment of glioblastoma multiforme (GBM).

13 Oct 2010

Retina Implant announces opening of new manufacturing plant in Tübingen-Reutlingen

Retina Implant AG, a leading developer of subretinal implants for the visually impaired, today announced the opening of a new manufacturing plant to meet anticipated demand for their implants. The company's second human clinical trial will be expanding outside of Germany in early 2011 to European countries including the U.K. and Italy and discussions are underway for potential clinical trials in the United States and Asia. Also looking ahead, the new facility meets manufacturing capabilities required for CE mark approval.

13 Oct 2010

PlastiPure awarded NIH and NSF grants to develop EA-Free material and products

PlastiPure, a safe plastics technology company, announced today that it has received two grants from the National Institute of Environmental Health and Safety (NIEHS), a division of the NIH, and an additional grant from the National Science Foundation (NSF). Collectively the grants fund formulation of a replacement for polycarbonate that is free of estrogenic activity (EA-Free), creating flexible food packaging that contains no EA, and developing a verifiably EA-Free baby bottle.

12 Oct 2010

Boyden reports 35% increase in demand for Senior R & D Managers in Life Sciences sector

Fresh hiring decisions are being made at senior management levels, due to CEOs' bold moves to reshape businesses to the more permanent competitive reality, according to the quarterly Boyden Executive Outlook, released today by Boyden Global Executive Search.

12 Oct 2010

New data-driven strategy helps to reduce healthcare costs

As rising health care costs continue to outpace inflation, some companies are trying a new data-driven strategy, reports the October Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).

12 Oct 2010

Essentialis receives patent for active component in DCCR product

Essentialis, Inc. announced today that the United States Patent & Trademark Office (USPTO) has issued U.S. Patent No. 7,799,777 entitled Salts of potassium ATP channel openers and uses thereof. The patent claims a novel composition of a polymorph of diazoxide choline, the active ingredient in the Essentialis lead product, DCCR. Essentialis has successfully completed phase 2b clinical trials with DCCR, showing a highly significant triglyceride reduction in dyslipidemic patients.

12 Oct 2010

Halozyme Therapeutics to advance core proprietary programs through key clinical inflection points

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced a focusing of its resources on advancing its core proprietary programs through key clinical inflection points in 2011 and 2012, and supporting strategic alliances with Roche and Baxter such as validation of Halozyme's commercial scale manufacturing process to produce kilogram quantities of enzyme.

12 Oct 2010

BioSystem Development completes $978,000 investment round

BioSystem Development, a privately held life science analytics company, announces a recently completed investment round that raised $978,000 (USD) in funding. The proceeds will be used to expand manufacturing infrastructure and to launch new products into the biopharmaceutical development market.

12 Oct 2010

Health Robotics enters distribution agreements with Newico and Apta Medica for 7 new European countries

Health Robotics today announced that it recently signed exclusive distribution agreements for its CytoCare, i.v.STATION, and i.v.SOFT world-leading technologies in seven new European countries with regional industry leaders Newico and Apta Medica, rapidly continuing on its worldwide quest to pervasively provide safe and cost-effective Intravenous (IV) Admixture Compounding Automation to hospitals all over the world.

11 Oct 2010

Valeant announces Alexza's receipt of FDA CRL for AZ-004 NDA

Valeant Pharmaceuticals International, Inc. announced today that Alexza Pharmaceuticals, Inc. has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding Alexza's New Drug Application (NDA) for AZ-004 (Staccato® loxapine) submitted as Adusuve™ Staccato® (loxapine) inhalation aerosol, 5 mg and 10 mg.

11 Oct 2010

Manufacturing News and Research

Further Reading

Delcath executes melphalan supply agreement with Synerx and Bioniche Teoranta

Prolong Pharmaceuticals receives $30 million from private investor group

Acetadote Injection is now commercially available in Australia

NinePoint announces completion of $33 million Series A financing

Highlighting calories, saturated fat, trans fat, and sodium in food packaging nutrition rating systems needed

Sunshine Biopharma to enter Adva-27a Phase I clinical trial for Multi-Drug Resistant breast cancer

Risingsun signs consent decree to stop selling unapproved drugs

Ligand launches Viviant in Japan and Spain for postmenopausal osteoporosis

Medicago and PATH partner on development of broad coverage influenza vaccine

Natus announces acquisition of Medix

ImmunoCellular develops ICT-107 cell-based vaccine for GBM treatment

Retina Implant announces opening of new manufacturing plant in Tübingen-Reutlingen

PlastiPure awarded NIH and NSF grants to develop EA-Free material and products

Boyden reports 35% increase in demand for Senior R & D Managers in Life Sciences sector

New data-driven strategy helps to reduce healthcare costs

Essentialis receives patent for active component in DCCR product

Halozyme Therapeutics to advance core proprietary programs through key clinical inflection points

BioSystem Development completes $978,000 investment round

Health Robotics enters distribution agreements with Newico and Apta Medica for 7 new European countries

Valeant announces Alexza's receipt of FDA CRL for AZ-004 NDA

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest Life Science News